RecruitingBPH (Benign Prostatic Hyperplasia)Lower Urinary Track Symptoms

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

Eligible age

18+ yrs

Accepts

Men

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.

Sponsor: Beth Israel Deaconess Medical Center

You may qualify if…

✓ 1. ≥18 yrs old on the day of study consent;
✓ 2. Finasteride has been recommended for treatment of BPH by a physician;
✓ 3. PSA \<20ng/ml within the last six months;
✓ 4. Willingness to maintain any current genitourinary medications (e.g., beta agonists, alpha blockers, anticholinergics);
✓ 5. Patient is able and willing to provide written informed consent.

You may not qualify if…

✕ 1. Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis;
✕ 2. Previous diagnosis with any prostatic malignancy or precancerous lesions (atypical glandular foci);
✕ 3. History of pelvic radiation;
✕ 4. Actively receiving intravesical therapy for bladder cancer;
✕ 5. Received treatment with any demethylating medications (azacitidine, decitabine, zebularine, guadecitabine, hydralazine);
✕ 6. Current use of warfarin;
✕ 7. Prior treatment with 5ARI medications (e.g., Finasteride or Dutasteride) in the last year;
✕ 8. Diagnosed with diabetes mellitus;

Where it's recruiting

Massachusetts

Boston

Source: ClinicalTrials.gov · NCT06944145 · last updated 2026-03-23